Floatz logo

TIPIRACIL

Solid Tumor Cancer

Shandong New Time Pharmaceutical Co., LTDSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

42 Active assets in the Solid Tumor Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Sarcoma Oncology Research Center, LLC
Phase 2CCC
DEXAMETHASONE
GlaxoSmithKline
Phase 3CCC
Casopitant
GlaxoSmithKline
Phase 3CCC
Zofran
GlaxoSmithKline
Phase 3CCC
Pembrolizumab
GV20 Therapeutics
Phase 1/2CCC

View all 50 →

Same molecule, other indications

TIPIRACIL is also rated in:

colorectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
69 / 100
View asset →
rectal cancerDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →